Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Other Accumulated Expenses (2016 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Other Accumulated Expenses for 10 consecutive years, with $2.3 million as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses rose 43.45% to $2.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Dec 2025, up 43.45% year-over-year, with the annual reading at $2.3 million for FY2025, 43.45% up from the prior year.
  • Other Accumulated Expenses hit $2.3 million in Q4 2025 for Rocket Pharmaceuticals, down from $2.7 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $3.1 million in Q2 2024 to a low of $482000.0 in Q4 2021.
  • Historically, Other Accumulated Expenses has averaged $1.7 million across 5 years, with a median of $1.7 million in 2023.
  • Biggest five-year swings in Other Accumulated Expenses: skyrocketed 371.58% in 2022 and later tumbled 44.17% in 2025.
  • Year by year, Other Accumulated Expenses stood at $482000.0 in 2021, then surged by 371.58% to $2.3 million in 2022, then fell by 22.04% to $1.8 million in 2023, then dropped by 8.3% to $1.6 million in 2024, then surged by 43.45% to $2.3 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for RCKT at $2.3 million in Q4 2025, $2.7 million in Q3 2025, and $1.7 million in Q2 2025.